Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 14;14:1458449. doi: 10.3389/fonc.2024.1458449

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Jung, Nelde, Maringer, Denk, Zieschang, Kammer, Özbek, Martus, Hackenbruch, Englisch, Heitmann, Salih and Walz

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Study population within the framework of current treatment guidelines of the medical societies in hematology and medical oncology of the German speaking countries (DGHO) (4). Study patients must have reached complete remission (CR) or CR with incomplete blood count recovery (CRi) with any type of first-line therapy. Allogeneic stem cell transplantation (allo-Tx) must not be a viable treatment option. AML, acute myeloid leukemia; APL, acute promyelocyte leukemia; 7 + 3, combinatorial treatment with cytarabine (7 days) and daunorubicin (3 days); CBF, core binding factor mutation; GO, gemtuzumab ozogamicin; mut, mutated; sAML, secondary AML; tAML, therapy-associated AML; LDAC, low-dose cytarabine; IDAC, intermediate-dose cytarabine; HDAC, high-dose cytarabine; CC-486, oral azacytidine; CPX-352, liposomal cytarabine and daunorubicin; HMA, hypomethylating agent.